Top Markets
Coin of the day
Novartis AG Novartis AG

Novartis AG

NVS
Rankning i aktier #47
Novartis AG researches, develops, manufactures, and markets healthcare products... Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company operates through two segments, Innovative Medicines and Sandoz. The Innovative Medicines segment offers prescription medicines for patients and healthcare providers. It also provides ophthalmology, neuroscience, immunology, hepatology, dermatology, respiratory, cardiovascular, renal, and metabolism medicine products. The Sandoz segment develops, manufactures, and markets finished dosage form medicines; active ingredients and finished dosage forms of small molecule pharmaceuticals to third parties; and retail generics and anti-infectives. It also provides active pharmaceutical ingredients and intermediates primarily antibiotics; protein- or other biotechnology-based products, including biosimilars; and biotechnology manufacturing services. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran; and a clinical collaboration with Kura Oncology, Inc. to evaluate the combination of Tipifarnib and Alpelisib in patients with head and neck squamous cell carcinoma. The company was incorporated in 1996 and is headquartered in Basel, Switzerland.
Aktiekurs
$150.75
Marknadsvärde
$291.41B
Förändring (1 dag)
1.44%
Förändring (1 år)
40.17%
Land
CH
Handel Novartis AG (NVS)

Kategori

P/S-tal för Novartis AG (NVS)
P/S-tal per 2026 TTM: 0
Enligt Novartis AG senaste finansiella rapporter och aktiekurs är det aktuella P/S-talet (TTM) 0. I slutet av 2026 hade företaget ett P/S-tal på 0.
Historik för P/S-tal för Novartis AG från 2026 till 2026
P/S-tal vid årets slut
År P/S-tal Ändra
Inte tillräckligt med data för de angivna datumen.
P/S-tal för liknande företag eller konkurrenter
Företag P/S-tal Skillnad i P/S-tal Land
14.26 -
US
4.96 -
GB
6.18 -
US
6.35 -
US
4.40 -
US